ESR1 and breast cancer: Although progesterone receptor (PR) activity has long been considered an indicator of functional estrogen response pathway [52], a small subset of primary breast cancer is classified as ER-negative/PR-positive with large studies showing an incidence of 3.4–3.8% [53,54].